Literature DB >> 17360739

Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Rong Rong1, S Gnanakaran, Julie M Decker, Frederic Bibollet-Ruche, Jesse Taylor, Jeffrey N Sfakianos, John L Mokili, Mark Muldoon, Joseph Mulenga, Susan Allen, Beatrice H Hahn, George M Shaw, Jerry L Blackwell, Bette T Korber, Eric Hunter, Cynthia A Derdeyn.   

Abstract

Autologous neutralizing antibodies (NAb) against human immunodeficiency virus type 1 generate viral escape variants; however, the mechanisms of escape are not clearly defined. In a previous study, we determined the susceptibilities of 48 donor and 25 recipient envelope (Env) glycoproteins from five subtype C heterosexual transmission pairs to NAb in donor plasma by using a virus pseudotyping assay, thereby providing an ideal setting to probe the determinants of susceptibility to neutralization. In the present study, acquisition of length in the Env gp120 hypervariable domains was shown to correlate with resistance to NAb in donor plasma (P = 0.01; Kendall's tau test) but not in heterologous plasma. Sequence divergence in the gp120 V1-to-V4 region also correlated with resistance to donor (P = 0.0002) and heterologous (P = 0.001) NAb. A mutual information analysis suggested possible associations of nine amino acid positions in V1 to V4 with NAb resistance to the donor's antibodies, and five of these were located within an 18-residue amphipathic helix (alpha2) located on the gp120 outer domain. High nonsynonymous-to-synonymous substitution (dN/dS) ratios, indicative of positive selection, were also found at these five positions in subtype C sequences in the database. Nevertheless, exchange of the entire alpha2 helix between resistant donor Envs and sensitive recipient Envs did not alter the NAb phenotype. The combined mutual information and dN/dS analyses suggest that unique mutational patterns in alpha2 and insertions in the V1-to-V4 region are associated with NAb resistance during subtype C infection but that the selected positions within the alpha2 helix must be linked to still other changes in Env to confer antibody escape. These findings suggest that subtype C viruses utilize mutations in the alpha2 helix for efficient viral replication and immune avoidance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360739      PMCID: PMC1900276          DOI: 10.1128/JVI.00257-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  MODELTEST: testing the model of DNA substitution.

Authors:  D Posada; K A Crandall
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

4.  Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties.

Authors:  M Poss; J Overbaugh
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

Authors:  C Cheng-Mayer; A Brown; J Harouse; P A Luciw; A J Mayer
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.

Authors:  B Etemad-Moghadam; G B Karlsson; M Halloran; Y Sun; D Schenten; M Fernandes; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  Evolution of envelope sequences from the genital tract and peripheral blood of women infected with clade A human immunodeficiency virus type 1.

Authors:  M Poss; A G Rodrigo; J J Gosink; G H Learn; D de Vange Panteleeff; H L Martin; J Bwayo; J K Kreiss; J Overbaugh
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  64 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

3.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

4.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Authors:  Aravind Basavapathruni; Wendy W Yeh; Rory T Coffey; James B Whitney; Peter T Hraber; Ayush Giri; Bette T Korber; Srinivas S Rao; Gary J Nabel; John R Mascola; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

7.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

8.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

Authors:  For Yue Tso; Federico G Hoffmann; Damien C Tully; Philippe Lemey; Robert A Rasmussen; Hong Zhang; Ruth M Ruprecht; Charles Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

10.  Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.

Authors:  Li-Hua Ping; Sarah B Joseph; Jeffrey A Anderson; Melissa-Rose Abrahams; Jesus F Salazar-Gonzalez; Laura P Kincer; Florette K Treurnicht; Leslie Arney; Suany Ojeda; Ming Zhang; Jessica Keys; E Lake Potter; Haitao Chu; Penny Moore; Maria G Salazar; Shilpa Iyer; Cassandra Jabara; Jennifer Kirchherr; Clement Mapanje; Nobubelo Ngandu; Cathal Seoighe; Irving Hoffman; Feng Gao; Yuyang Tang; Celia Labranche; Benhur Lee; Andrew Saville; Marion Vermeulen; Susan Fiscus; Lynn Morris; Salim Abdool Karim; Barton F Haynes; George M Shaw; Bette T Korber; Beatrice H Hahn; Myron S Cohen; David Montefiori; Carolyn Williamson; Ronald Swanstrom
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.